Mirum Pharmaceuticals, Inc. (ETR:08D)
Germany · Delayed Price · Currency is EUR | Market Cap | 5.44B +71.5% |
| Revenue (ttm) | 590.69M +42.2% |
| Net Income | -795.95M |
| EPS | -13.50 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 86.54 |
| Previous Close | 82.48 |
| Day's Range | 86.26 - 86.76 |
| 52-Week Range | 70.54 - 113.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.
Financial numbers in USD Financial StatementsNews
GeneDx, Mirum launch sponsored testing programs
GeneDx (WGS) announced a collaboration with Mirum (MIRM) to offer no-cost exome testing for eligible patients across three sponsored testing programs: cholestasis, early-onset cataracts, and peroxisom...
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.
Mirum Pharmaceuticals price target raised to $160 from $155 at Cantor Fitzgerald
Cantor Fitzgerald analyst Josh Schimmer raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $160 from $155 and keeps an Overweight rating on the shares.
Mirum Pharmaceuticals price target raised to $202 from $200 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $202 from $200 and keeps a Buy rating on the shares. The company reported “another…
Mirum Pharmaceuticals price target raised to $167 from $144 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $167 from $144 and keeps an Outperform rating on the shares. Livmarli delivered another strong quar...
Mirum Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 net product sales reached $186M, lifting FY 2026 guidance to $715M-$720M. Commercial growth, ATEBRIOZ’s launch and multiple 2027 regulatory milestones underpin the next growth phase.
Mirum Pharmaceuticals Earnings release: Q3 2026
Mirum Pharmaceuticals released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Mirum Pharmaceuticals Quarterly report: Q3 2026
Mirum Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 3, 2026.
Mirum Pharmaceuticals raises FY26 revenue view to $715M-$720M, consensus $698.1M
The company guided $680M-$700M.
Mirum Pharmaceuticals reports Q3 EPS (87c), consensus (41c)
Reports Q3 revenue $185.7M, consensus $178.0M. “The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across…
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update.
Mirum Pharmaceuticals Slides: Corporate presentation
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Mirum Pharmaceuticals showcases momentum across rare liver disease portfolio
Mirum Pharmaceuticals (MIRM) announced that data from its rare liver disease portfolio will be presented at the American Association for the Study of Liver Diseases’ The Liver Meeting 2026, taking…
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026.
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026.
Mirum announces results from Cohort 2 of Progress study of Atebrioz
Mirum Pharmaceuticals (MIRM) announced positive results from Cohort 2 of the pivotal Progress study of Atebrioz, an oral activin receptor-like kinase 2 inhibitor, in pediatric patients aged 6 to less…
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum Pharmaceuticals’ brelovitug receives FDA orphan designation
Mirum Pharmaceuticals (MIRM)’ brelovitug received FDA orphan designation for the treatment of active hepatitis delta virus infection, according to a post to the agency’s website.
Mirum Pharmaceuticals price target raised to $145 from $140 at TD Cowen
TD Cowen analyst Joseph Thome raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $145 from $140 and keeps a Buy rating on the shares. The firm updated its…
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals Slides: Conference presentation
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 15, 2026.
Mirum Pharmaceuticals price target raised to $156 from $136 at Stifel
Stifel raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $156 from $136 and keeps a Buy rating on the shares. The firm is citing the company’s recent clinical…
Mirum Pharmaceuticals price target raised to $146 from $135 at Evercore ISI
Evercore ISI raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $146 from $135 and keeps an Outperform rating on the shares.
Mirum Pharmaceuticals price target raised to $152 from $137 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $152 from $137 and keeps an Overweight rating on the shares. Data from the Phase 3 EXPAND study…